Market research
ECQ.F PharmAust Limited
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 69M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.55
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU0000357261
- Market cap
- 69M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.55
About
About PharmAust Limited
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ECQ.F discussion.
5 years, 5 months ago
PharmAust Limited is currently in a long term downtrend where the price is trading 12.4% below its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.7.
PharmAust Limited's total revenue sank by 0.0% to $1M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-242K since the same quarter in the previous year.
Finally, its free cash flow grew by 56.3% to $-314K since the same quarter in the previous year.
Based on the above factors, PharmAust Limited gets an overall score of 2/5.